OCTOBER 2012 Interesting Case 1. 2 View the following cytology images and then think about your diagnosis. Slides 12 onwards provide the answer and follow.

Slides:



Advertisements
Similar presentations
An audit of Endometrial Pathology cases referred to NGOC Dr Paul Cross Consultant Cellular Pathologist Queen Elizabeth Hospital Gateshead.
Advertisements

Endometrial Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
Malignant diseases of the uterus
Endometrial Cancer Tseng Jen-Yu 02/05/2007 Tseng Jen-Yu 02/05/2007.
 - an important step in surgical staging for uterine cancer (FIGO 1988)  Stated as 
Precancer, benign and malignant tumors of the uterus and ovary Eduard Kučera.
A significant increase in the incidence of endometrial cancer. This increased incidence of endometrial cancer has been widely interpreted to be a result.
District 1 ACOG Medical Student Teaching Module 2009
Carcinoma of the Endometrium1 CARCINOMA OF THE ENDOMETRIUM Wen Di, M.D. , Ph.D.
Xi-Shi Liu Obstetrics and Gynecology Hospital Fudan university
Uterine corpus. benign diseases: - endometritis - endometriosis and adenomyosis - endometrial polyps precursor lesions of endometrial carcinoma endometrial.
Dr P Mukonoweshuro Consultant Pathologist RUH Bath
Endometrial Hyperplasia
Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY The Clinical.
Straight tubules of proliferative endometrium Early secretory endometrium with subnuclear vacuoles.
CARCINOMA OF THE ENDOMETRIUM
NEOPLASIA (Malignant Tumors)
Endometrial Cancer ASSOCIATE PROFESSOR Iolanda Blidaru MD, PhD.
Malignant disease of the body of the uterus  The most common malignant diseas affecting the uterus is endometrial carcinoma, which arises from the lining.
Gynaecologische Tumoren: Internationale richtlijnen en Nieuwe perspectieven in diagnostiek en behandeling SYMPOSIUM ONCOLOGIE – 7 JUNI 2008 Philippe Van.
 The term post menopause is applied to women who have not experienced a menstrual bleed for a minimum of 12 months, assuming that they do still have.
Chapter 4 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
Post-menopausal bleeding PV Dr Nasira Sabiha Dawood.
Multiple adenocarcinomas and synchronous leiomyosarcoma of the colon: a case report M.C. De Nisi, C.Maggiore, C.Minacci, M.Stumpo, M.L. Palmeri, L. Pergola,
Carcinoma Corpus Uteri
Endometrial Carcinoma
Are there benefits from chemotherapy to early endometrial cancer
Interesting Case October Interesting Case View the following cytology images and then think about your diagnosis. Slides 12 onwards provide the.
Female reproductive system 89Chronic cervicitis 302Naboth cysts 141Cervical squamous cell carcinoma 45Endometrial hyperplasia 129Endometrial carcinoma.
Prof Greta Dreyer University of Pretoria
醫學五 楊世慧 詹舜文 屠冠翔 pathology.
Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan.
By: Maureen Jaminal BIOL 316
Uterine Cancers A. Alobaid, MBBS, FRCS(C), FACOG Consultant, Gynecologic Oncology Assistant professor, KSU Medical Director, Women’s Specialized Hospital.
Female Genital Tract I, Case 3
TEMPLATE DESIGN © Endometrial large cell neuroendocrine carcinoma : a case report Reina Sato, Aiko Kawano, Hiroyuki Shigeta.
Bladder cancer is the second most common cancer of the genitourinary tract. The incidence is higher in whites than in African Americans. The average age.
Dr. Saadeh Jaber OBGYN consultant Epidemiology Second most common gynecological cancer. >35, median 70 It accounts for deaths more than cancer of.
Female reproductive system and breast 303Endometriosis 308Ectopic (tubal) pregnancy 92Hydatidiform mole 93Choriocarcinoma 94Fibrocystic breast change 22Hyaline.
17 th century microscopes In The Name of God PARISA REZAEI,M.D.,AP.CP.
FEMALE GENITAL SYSTEM 2 nd Practical Session Reproduction block Pathology Dept, KSU.
TEMPLATE DESIGN © Uterine sarcomas in RIPAS Hospital, Brunei; a 10 year retrospective study. Dr Alice Kurien, Dr Saw Ohnmar,
Vulvar Cancer Women’s Hospital,School of Medicine Zhejiang University.
Ovarian tumors. *Classification: I. Tumors arising from the surface epithelium:I. Tumors arising from the surface epithelium: Serous tumors: (benign,
By Dr. Nadia Saddam AL.Assady C.A.B.O.G. Malignant disease of the uterus: Endomaterial carcinoma (CA) has good prognosis in which (5 years survival rate.
UTERINE CORPUS. ACUTE ENDOMETRITIS Is most often related to intrauterine trauma from instrumentation, intrauterine contraceptive device or complications.
Tamoxifen associated changes
Ovarian Tumors Epidemiology - Ranks below only carcinoma of the cervix and the endometrium. -Ovarian cancer accounts for 6% of all cancers in the female.
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
KARIMA SALAMA ENDOMETRIAL CANCER. Epidemiology Most common gynecological cancer in the developed countries, with an incidence of 12.9 per 100,000 women.
Endometrial polyp, hyperplasia, carcinoma Dr: Salah Ahmed.
Cervical and uterine diseases LAB 2009 Prof Dr Suzan Kato.
Female Reproductive Unit -Introduction
KCP792 79/ 여자, 자궁경부 / 흉수 성균관의대 병리학교실 강북삼성병원 병리과 채승완.
Cancer of the Uterine Corpus and Cervix David Toub, M.D. Medical Director Newton Interactive.
case report Title: uterine mass Master: Dr.Mahzooni Resident: Dr.Soleimani 92/7/6.
M.D. Browning, M.D. ‘77.  Most Common Cancer of Female Reproductive System  60,000/year with 10,000 deaths  Normal Cells in the Endometrium.
Malignant disease of the body of the uterus
Malignant disease of the body of the uterus
Intravascular leiomyomatosis (A rare case report)
Malignant disease of the body of the uterus
930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,
Uterine cancer Uterine mesenchymal neoplasms
Adult granulosa cell tumor and associated cancers Anna Lund Rasmussen, Finn Lauszus, Anne Hammer PhD Department of Gynecology & Obstetrics Herning Hospital.
Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis
ENDOMETRIAL CARCINOMA
Presentation transcript:

OCTOBER 2012 Interesting Case 1

2 View the following cytology images and then think about your diagnosis. Slides 12 onwards provide the answer and follow up with corresponding histology

Case submitted by 3 Nick Dudding FIBMS, Advanced Biomedical Scientist Practitioner, Sheffield, UK. Assistant Director. East Pennine Cytology Training Centre. Callum Bowler FIBMS. Advanced Biomedical Scientist Practitioner. James Cook University Hospital. Middlesbrough. UK

Case history 4 67 year old Female. SurePath™ LBC sample Modified Papanicoloau staining All photomicrographs are x 400

5 Figure 1.

6 Figure 2.

7 Figure 3.

8 Figure 4.

9 Figure 5.

10 Figure 6.

What do you think this represents ? 11 Tissue repair Clear cell carcinoma Decidual change Squamous cell carcinoma Carcinosarcoma (mixed Müllerian carcinoma) The answer is on the next page

Answer 12 It is E Carcinosarcoma or mixed Müllerian carcinoma

Cytomorphology 13 Figure 1 shows one exfoliated ball of cells with slightly eccentric nuclear placement and prominent nucleoli. This would represent the carcinomatous elements. Figure 2 shows a single, but highly abnormal looking cell with multiple nucleoli contained within two enlarged nuclei. The remaining figures show a variety of enlarged or elongated cells, all with nucleoli, but also presenting with plentiful cyanophilic cytoplasm. These almost certainly represent the sarcomatous elements.

Histopathology 14 The uterus showed a high grade carcinosarcoma composed predominantly of sarcoma (Figures b – c) with rhabdomyoblasts and a minor component of serous adenocarcinoma (Figure a). The carcinosarcoma infiltrated a leiomyoma, but not the myometrium and hence is best regarded as FIGO IB. Focal vascular invasion was seen. The cervix, omentum and right and left ovaries and tubes showed no significant histological abnormalities.

15 Figure A.

16 Figure B.

17 Figure C.

Disease Fact Sheet 18 Malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor, MMMT and carcinosarcoma, is a malignant neoplasm arising in the uterus. (1) Although MMMT can be picked up by cytology it generally presents in a postmenopausal patient being investigated for uterine bleeding, and found to have an enlarged uterus

Disease Fact Sheet 19 They are usually large, soft polypoid tumours occuring in the endometrium and myometrium. They are composed of a mixture of carcinomatous and sarcomatous elements. (2,3) The appearance of the sarcomatous elements divides the entity into two types, homologus and heterologous. In the homologous type, the sarcomatous component resembles tissues found in the uterus such as endometrial stromal sarcoma or leiomyosarcoma. In the heterologous type the sarcomatous element comprises tissues not found in the uterus, such as cartilage, skeletal muscle and/or bone.

Disease Fact Sheet 20 MMMT account for between two and five percent of all tumors derived from the body of the uterus, and are found predominantly in postmeonopausal women with an average age of 66 years.(4) Risk factors are similar to those of adenocarcinomas and include obesity, exogenous estrogen therapies, and nulliparity. Less well- understood but potential risk factors include tamoxifen therapy and pelvic irradiation (5)

Disease Fact Sheet 21 Outcome of MMMTs is determined primarily by depth of invasion and stage. As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with serous differentiation. MMMTs are highly malignant; a stage I tumor has an expected five-year survival rate of 50%, while the overall five-year survival rate is less than 20%. [5]

22 References 1. Barwick KW, Livolski VA. Malignant mixed Müllerian tumours of the uterus. Am J Surg Pathol 1979, 3: 125 – Silverberg SG, Major FJ,Blessing JA, Fetter B, Askin FB, Liao sy, Miller A. Carcinosarcoma (malignant mixed mesodermal tumour 3. A gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol1990, 9: 647 – Chuang JT, Van Velden DJJ, Graham JB Carcinosarcoma and mixed mesodermal tumour of the uterine corpus. Review of 49 cases. Obstet Gynecol 1970, 35: Siegal GP; Chhieng DC (2005). Updates in diagnostic pathology. Berlin: Springer. pp ISBN